1. Home
  2. TOI vs NGNE Comparison

TOI vs NGNE Comparison

Compare TOI & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TOI
  • NGNE
  • Stock Information
  • Founded
  • TOI 2007
  • NGNE 2003
  • Country
  • TOI United States
  • NGNE United States
  • Employees
  • TOI N/A
  • NGNE N/A
  • Industry
  • TOI Medical/Nursing Services
  • NGNE Biotechnology: Pharmaceutical Preparations
  • Sector
  • TOI Health Care
  • NGNE Health Care
  • Exchange
  • TOI Nasdaq
  • NGNE Nasdaq
  • Market Cap
  • TOI 393.4M
  • NGNE 325.3M
  • IPO Year
  • TOI N/A
  • NGNE N/A
  • Fundamental
  • Price
  • TOI $3.11
  • NGNE $17.97
  • Analyst Decision
  • TOI Strong Buy
  • NGNE Strong Buy
  • Analyst Count
  • TOI 1
  • NGNE 7
  • Target Price
  • TOI $6.00
  • NGNE $41.86
  • AVG Volume (30 Days)
  • TOI 1.5M
  • NGNE 132.4K
  • Earning Date
  • TOI 11-12-2025
  • NGNE 11-14-2025
  • Dividend Yield
  • TOI N/A
  • NGNE N/A
  • EPS Growth
  • TOI N/A
  • NGNE N/A
  • EPS
  • TOI N/A
  • NGNE N/A
  • Revenue
  • TOI $424,376,000.00
  • NGNE N/A
  • Revenue This Year
  • TOI $21.96
  • NGNE N/A
  • Revenue Next Year
  • TOI $20.34
  • NGNE N/A
  • P/E Ratio
  • TOI N/A
  • NGNE N/A
  • Revenue Growth
  • TOI 17.53
  • NGNE N/A
  • 52 Week Low
  • TOI $0.13
  • NGNE $6.88
  • 52 Week High
  • TOI $4.50
  • NGNE $74.49
  • Technical
  • Relative Strength Index (RSI)
  • TOI 38.10
  • NGNE 40.48
  • Support Level
  • TOI $2.98
  • NGNE $18.37
  • Resistance Level
  • TOI $3.41
  • NGNE $20.72
  • Average True Range (ATR)
  • TOI 0.17
  • NGNE 1.28
  • MACD
  • TOI -0.04
  • NGNE -0.14
  • Stochastic Oscillator
  • TOI 22.81
  • NGNE 23.31

About TOI The Oncology Institute Inc.

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: